Renal anemia in patients with maintenance peritoneal dialysis and Related Factors: A single-center study
Received date: 2022-09-04
Online published: 2023-01-18
Objective To evaluate renal anemia in patients with maintenance peritoneal dialysis, analyze factors affecting hemoglobin in patients with maintenance peritoneal dialysis, and guide clinical intervention and treatment. Methods The demographic characteristics and clinical data of 238 patients with peritoneal dialysis who were regularly followed up in the Peritoneal Dialysis Center of Linyi People's Hospital of Shandong Province from January 2011 to December 2020 were retrospectively analyzed. Hematocrystalin (Hb)≥110 g/L was used as the cutoff value. They were divided into the qualified Hb group (Hb≥110 g/L) and the unqualified Hb group (Hb<110 g/L). Both groups were compared in terms of gender, age, basic disease, biochemical examination, urea clearance index (KT/V), peritoneal balance test results, and other factors. In this center, the qualified rate of hemoglobin treatment and its influencing factors in patients undergoing peritoneal dialysis were analyzed. Results ①The mean Hb of recruited patients was (103.85±19.13) g/L. There were 108 cases (45.38%) in the qualified Hb group and 130 cases (54.62%) in the unqualified Hb group. ② Univariate analysis showed that the Hb level was positively related to total KT/V (r=0.282, P<0.05), peritoneal KT/V (r=0.230, P<0.05) and ultra-filtration amount (r=0.146, P<0.05), which was negatively correlated with body mass index (r=0.154, P<0.05). ③ Multivariate logistic regression analysis showed that body mass index (BMI), low albumin, creatinine, and ultrafiltration volume were risk factors for Hb in patients with continuous ambulatory peritoneal dialysis (CAPD). Conclusion A patient's BMI, albumin, creatinine, and ultrafiltration volume may be used to predict eligibility for Hb therapy during peritoneal dialysis. It is more likely that Hb would qualify for peritoneal dialysis patients with a lower BMI, a higher ultra-filtration volume, and a higher peritoneal KT/V and total KT/V.
Key words: peritoneal dialysis; anemia; percent of pass; factors affecting
Hongtao Zhang , Zhikui Wang . Renal anemia in patients with maintenance peritoneal dialysis and Related Factors: A single-center study[J]. Clinical Focus, 2022 , 37(12) : 1099 -1103 . DOI: 10.3969/j.issn.1004-583X.2022.12.006
| [1] | Ene-Iordache B, Perico N, Bikbov B, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): A cross-sectional study[J]. Lancet Glob Health, 2016, 4(5):307-319. |
| [2] | Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: A cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. |
| [3] | Li PK, Chow KM, Van de Luijtgaarden MW, et al. Changes in the worldwide epidemiology of peritoneal dialysis[J]. Nat Rev Nephrol, 2017, 13(2):90-103. |
| [4] | 陈香美, 周建辉. 中国腹膜透析技术发展现状与未来[J]. 中国实用内科杂志, 2013, 33(6):413-415. |
| [5] | 中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志, 2021, 101(20):1463-1502. |
| [6] | Rayner HC, Pisoni RL, Juergen B, et al. Mortality and hospitalization in haemodialysis patients in five European countries:Results from the dialysis outcomes and practice patterns study (DOPPS)[J]. Nephrol Dial Transplant, 2004, 19(1):108-120. |
| [7] | Port FK, Pisoni RL, Bommer J, et al. Improving outcomes for dialysis patients in the international dialysis outcomes and practice patterns study[J]. Clin J Am Soc Nephrol, 2006, 1(2):246-255. |
| [8] | Cernaro V, Coppolino G, Visconti L, et al. Erythropoiesis and chronic kidney disease-related anemia: From physiology to new therapeutic advancements[J]. Med Res Rev, 2019, 39(2):427-460. |
| [9] | 李振元, 张贺, 陆晓蓉, 等. 腹膜透析患者血红蛋白达标率及其相关因素分析[J]. 中国血净化, 2017, 16(2):121-125. |
| [10] | Sch?mig M, Eisenhardt A, Ritz E. The microinflammatory state of uremia[J]. Blood Purif, 2000, 18(4):327-332. |
| [11] | 何玉. 单中心腹膜透析相关性腹膜炎的致病菌及其药物敏感分析[J]. 中国卫生标准管理, 2022, 13(2):36-39. |
| [12] | 田秀娟, 许国双. 单中心腹膜透析患者隧道感染的临床特征和治疗效果[J]. 中国血液净化, 2021, 20(7):469-472. |
| [13] | Dai L, Golembiewska E, Lindholm B, et al. End-stage renal disease, inflammation and cardiovascular outcomes[J]. Contrib Nephrol, 2017, 191:32-43. |
| [14] | 袁静, 杨宇齐, 刘璐, 等. 血小板/淋巴细胞比值与腹膜透析患者频发性腹膜透析相关性腹膜炎的关系[J]. 中华肾脏病杂志, 2021, 37(4):327-332. |
| [15] | McDonald SP, Collins JF, Johnson DW. Obesity is associated with worse peritoneal dialysis outcomes in the Australia and New Zealand patient populations[J]. J Am Soc Nephrol, 2003, 14(11):2894-2901. |
| [16] | 张兰, 马迎春. 慢性肾脏病患者胰岛素抵抗的研究进展[J]. 临床内科杂志, 2014, 31(8):570-571. |
| [17] | Kramer H, Tuttle KR, Leehey D, et al. Obesity management in adults with CKD[J]. Am J Kidney Dis, 2009, 53(1): 151-165. |
| [18] | Turkmen K, Guney I, Yazici R, et al. Health-related quality of life, depression and mortality in peritoneal dialysis patients in Turkey: Seven-year experience of a center[J]. Ren Fail, 2014, 36(6): 859-864. |
| [19] | 赵玉超, 赵慧萍, 武蓓, 等. 维持性腹膜透析患者红细胞寿命及其影响因素分析[J]. 中国血液净化, 2022, 21(5):322-325, 349. |
| [20] | 张渊, 孟祥龙, 洪大情, 等. 维持性血液透析患者透析充分性与肾性贫血的关系[J]. 中国血液净化, 2014, 13(4):311-312, 332. |
| [21] | 张宏涛, 杨雨, 王志奎. 腹膜透析患者心力衰竭治疗药物研究进展[J]. 临床荟萃, 2022, 37(6): 556-559. |
| [22] | 张宏涛, 蔄瑜琳, 王加如, 等. 维持性腹膜透析患者肾性贫血现状分析及治疗进展[J]. 临床医学进展, 2022, 12(11): 9898-9904. |
| [23] | 周任, 陈亚婷, 张永. 罗沙司他治疗血液透析肾性贫血患者有效性和安全性的Meta分析[J]. 临床荟萃, 2022, 37(4):305-310. |
/
| 〈 |
|
〉 |